Hüsnü Pullukçu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hüsnü Pullukçu has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Ahmet Cagkan Inkaya
Department of Infectious Diseases and Clinical Microbiology, Hacettepe University Faculty of Medicine, Ankara, Turkey
1 shared publication - Aslıhan Candevir
Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Çukurova University, Adana, Turkey
1 shared publication - Ayşe Özlem Mete
Infectious Diseases and Clinical Microbiology, Gaziantep University, Gaziantep, Turkey, Turkey (Türkiye)
1 shared publication - Behice Kurtaran
Department of Infectious Diseases and Clinical Microbiology, Acıbadem Adana Hospital, Adana 01130, Türkiye
1 shared publication - Damla Ertürk
Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Çukurova University, Adana 01330, Türkiye
1 shared publication - Dilara Inan
Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Akdeniz University, Antalya 07070, Türkiye
1 shared publication
Latest Publications
- Open Access
- 28 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (19) , 8672
Baseline Liver Metabolic Health in Newly Diagnosed People Living with HIV Compared with HIV-Negative Controls: Cross-Sectional Findings from the Prospective MASHIV-TR Cohort
Metabolic dysfunction-associated steatotic liver disease (MASLD) is an important comorbidity in people living with HIV (PLWH), yet most data derive from individuals receiving antiretroviral therapy (ART). In the baseline cross-sectional analysis of the prospective multicentre MASHIV-TR cohort (nine centres, Türkiye), we compared 250 newly diagnosed, ART-naïve PLWH and 161 HIV-negative controls. Hepatic steatosis and liver stiffness were assessed by vibration-controlled transient elastography; MASLD was defined as hepatic steatosis, indicated by CAP ≥ 248 dB/m together with at least one cardiometabolic risk factor. MASLD prevalence was similar in the two groups (25.2% vs. 30.4%; p = 0.245), and HIV status was not independently associated with MASLD. Triglyceride level was independently associated with CAP in PLWH (+10.69 dB/m per 50 mg/dL) and in controls (+9.26 dB/m), whereas CD4 and CD8 counts, the CD4/CD8 ratio and HIV-RNA were not associated with the liver outcomes. Before ART, hepatic steatosis tracked metabolic rather than HIV-specific markers.
- 28 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (19) , 8672
Open AccessBaseline Liver Metabolic Health in Newly Diagnosed People Living with HIV Compared with HIV-Negative Controls: Cross-Sectional Findings from the Prospective MASHIV-TR Cohort
Metabolic dysfunction-associated steatotic liver disease (MASLD) is an important comorbidity in people living with HIV (PLWH), yet most data derive from individuals receiving antiretroviral therapy (ART). In the baseline cross-sectional analysis of the prospective multicentre MASHIV-TR cohort (nine centres, Türkiye), we compared 250 newly diagnosed, ART-naïve PLWH and 161 HIV-negative controls. Hepatic steatosis and liver stiffness were assessed by vibration-controlled transient elastography; MASLD was defined as hepatic steatosis, indicated by CAP ≥ 248 dB/m together with at least one cardiometabolic risk factor. MASLD prevalence was similar in the two groups (25.2% vs. 30.4%; p = 0.245), and HIV status was not independently associated with MASLD. Triglyceride level was independently associated with CAP in PLWH (+10.69 dB/m per 50 mg/dL) and in controls (+9.26 dB/m), whereas CD4 and CD8 counts, the CD4/CD8 ratio and HIV-RNA were not associated with the liver outcomes. Before ART, hepatic steatosis tracked metabolic rather than HIV-specific markers.